Monoclonal-Antibody Biopharma (1,910 companies)
281 CompaniesAccess all companies
Spotfolio tracks over one million companies in technology industries.
There are 281 companies in the field of Biopharma on spotfolio that produce or deliver products, that utilize or research technologies or that are otherwise engaged in topics such as Antibody, Clinical, Cell, Therapeutic, Drug, Monoclonal, Biopharmaceutical, Disease, Monoclonal-Antibody .
Early-stage companies (67)
Established companies (175)
The majority of these companies is located in the following countries.
United States (149)
United Kingdom (15)
Example CompaniesFind companies in your area
Kymab Kymab Limited
enter to search KY1005 OX40L monoclonal antibody Atopic Dermatitis, Phase 2a KY1005 is a human monoclonal antibody that targets OX40L, a key regulator
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L Source: Kymab Continues ...
result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand ...
pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination ...
a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune mediated diseases and immuno-oncology
9598496 B2 - Shimosaki, S. et al. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma
Outlook Therapeutics Outlook Therapeutics, Inc.
ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications. Our team is energized
humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (or mAb) that inhibits VEGF and associated angiogenic activity. ONS-5010
proprietary compounds which inhibit complement component C6. The humanized monoclonal antibody CP 010 binds to C6 in circulation. By inhibiting C6 in circulation
development of new programs. The lead program CP 010 is a humanized monoclonal antibody that strongly binds to C6 in circulation and systemic delivery results
D2/D3, Monoclonal Antibody , clone 281/A2KC4 - 25OH Vitamin D2/D3, Monoclonal Antibody , clone 281/A2LB5 - 25OH Vitamin D2/D3, Monoclonal Antibody , clone ...
D2/D3, Monoclonal Antibody , clone 281/A2NE3 - 25OH Vitamin D2/D3, Monoclonal Antibody , clone 281/A2KC4 - 25OH Vitamin D2/D3, Monoclonal Antibody , clone
TopicsSearch by any topic
Only spotfolio allows for searching with detailed technology terms, as we provide you with all topics that technology companies talk about.
Companies addressing these topics might be of specific interest to you, as they share more specific, niche topics.
The following topics addressed by the majority of companies help you discover major players in the field.
All companies in this field address the following more general topics.
Use CasesRegister now
Technology scouting is the basis for your innovation management, identifies new technological developments as early as possible and protects you from disruptive business models.
Collect technology leaders, providers, start ups and potential new partners in lists via simple tagging to take further steps with your team.